GO:0005095 GTPase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005095 (GTPase inhibitor activity) describes a molecular function that stops, prevents, or reduces the activity of any enzyme that hydrolyzes GTP to GDP and orthophosphate [1, 4].
• GTPase inhibitors work by stabilizing the GTP-bound state of small GTPases such as RAS, Rac1, and Drp1, thereby blocking downstream signaling [1, 2, 4].
• Pharmacological inhibitors targeting the switch II pocket of KRAS(G12D) allosterically freeze the nucleotide-binding site and arrest the GTPase cycle.
• Dysregulated GTPase inhibitor activity is implicated in cancer, pulmonary hypertension, and neurodegeneration through proteins like LRRK2 [2, 4, 8].
• CRISPR knockout, point-mutation knock-in, and overexpression models are essential for dissecting how GTPase inhibitors control cellular processes [1, 5].
• EDITGENE provides end-to-end CRISPR cell model services to study GTPase inhibitor activity in disease-relevant contexts [1, 4].
Description
GTPase inhibitor activity (GO:0005095) is a molecular function that stops, prevents, or reduces the activity of any enzyme catalyzing the hydrolysis of GTP to GDP and orthophosphate. This function is critical because small GTPases act as molecular switches that cycle between active GTP-bound and inactive GDP-bound states, and their precise regulation controls cell proliferation, cytoskeletal dynamics, and membrane trafficking [2, 4]. Researchers study GTPase inhibitor activity to understand how cells maintain signaling fidelity and to develop therapies that correct aberrant GTPase signaling in diseases such as cancer and pulmonary hypertension [1, 4]. The term encompasses both endogenous proteins that negatively regulate GTPases and pharmacological agents that block GTP hydrolysis, as exemplified by allosteric inhibitors of KRAS(G12D) and Drp1 [4, 6]. Because many GTPases are validated drug targets, defining the mechanisms of their inhibition is a central goal in molecular pharmacology and precision medicine [1, 5].
GTPase inhibitor activity At A Glance
| GO ID | GO:0005095 |
|---|---|
| GO term | GTPase inhibitor activity |
| Ontology | molecular_function |
| Synonym | GIP |
| Definition | Stops, prevents or reduces the activity of any enzyme that catalyzes the hydrolysis of GTP to GDP and orthophosphate. |
| Major function | Negative regulation of GTPase-mediated GTP hydrolysis, stabilizing the GTP-bound active state. |
| Example targets | KRAS, Rac1, Drp1, LRRK2, NRAS |
| Disease relevance | Cancer, pulmonary hypertension, neurodegeneration, melanoma |
| Research methods | CRISPR knockout, point-mutation knock-in, overexpression, pharmacological inhibition |
What Is GO:0005095?
GTPase inhibitor activity (GO:0005095) is defined as a molecular function that stops, prevents, or reduces the activity of any enzyme that catalyzes the hydrolysis of GTP to GDP and orthophosphate. In practice, this means a protein or small molecule binds to a GTPase and blocks its ability to convert GTP into GDP, thereby locking the GTPase in its active, GTP-bound conformation [4, 6]. This function is distinct from GTPase activator activity (GAP activity), which accelerates GTP hydrolysis; instead, GTPase inhibitor activity opposes hydrolysis or stabilizes the GTP-bound state.
Why Is GTPase inhibitor activity Important in Cell Biology?
GTPase inhibitor activity is fundamentally important because it provides a brake on GTPase signaling, and loss of this brake leads to constitutive activation of pathways that drive cancer, cardiovascular disease, and neurodegeneration [1, 2, 4, 8]. Pharmacological restoration of GTP hydrolysis by mutant RAS demonstrates that targeting this activity can reverse oncogenic signaling. Similarly, inhibition of Drp1 GTPase activity ameliorates pulmonary hypertension, and allosteric inhibition of LRRK2 is a therapeutic strategy for Parkinson's disease [4, 8]. Understanding GTPase inhibitor activity therefore informs both basic cell biology and the development of precision therapeutics [5, 6].
• Controls the duration and amplitude of GTPase signaling, preventing constitutive activation of growth pathways.
• Pharmacological inhibition of mutant KRAS(G12D) by switch II pocket inhibitors arrests the GTPase cycle and suppresses tumor growth.
• Drp1 GTPase inhibitors reduce mitochondrial fission and improve outcomes in pulmonary hypertension models.
• LDHA activates Rac1 GTPase as a noncanonical mechanism, highlighting metabolic control of GTPase inhibitor activity.
• LRRK2 allosteric inhibitors are being developed for Parkinson's disease, where hyperactive GTPase signaling is pathogenic.
• Casein kinase 1δ targeting suppresses oncogenic NRAS-driven melanoma, linking kinase signaling to GTPase inhibition.
• GTPase inhibitor activity is essential for T cell memory development via AMPK-coupled SENP1-Sirt3 signaling.
• Elongation factor 2 (eEF2) is a GTPase whose inhibition affects protein translation and is a cancer therapeutic target.
• CRISPR-based models enable causal testing of GTPase inhibitor genes in disease contexts [1, 5].
• Bioinformatics and library screening accelerate discovery of novel GTPase inhibitors [1, 4].
Molecular Mechanism of GTPase inhibitor activity
GTPase cycle and the need for inhibition
In simple terms: GTPases are like molecular switches that are ON when bound to GTP and OFF when bound to GDP; GTPase inhibitor activity keeps them ON by preventing GTP hydrolysis.
Small GTPases such as RAS, Rac1, and Drp1 cycle between GTP-bound active and GDP-bound inactive states [1, 2, 4]. Hydrolysis of GTP to GDP is catalyzed by the GTPase itself and is often accelerated by GTPase-activating proteins (GAPs). GTPase inhibitor activity opposes this hydrolysis, either by blocking the catalytic site or by allosterically stabilizing the GTP-bound conformation [1, 6]. This function is critical for maintaining signaling thresholds in processes like cell proliferation, cytoskeletal remodeling, and mitochondrial dynamics [2, 4].
Allosteric inhibition of KRAS(G12D) by switch II pocket binders
In simple terms: Some drugs stick to a pocket on mutant KRAS and freeze it in a shape that cannot hydrolyze GTP, stopping cancer growth.
The switch II pocket inhibitor allosterically freezes the KRAS(G12D) nucleotide-binding site and arrests the GTPase cycle. This mechanism exemplifies GTPase inhibitor activity at the molecular level: rather than competing with GTP, the inhibitor induces a conformational change that prevents hydrolysis. Pharmacological restoration of GTP hydrolysis by mutant RAS has been achieved with small molecules that promote the active state's transition to an inactive-like conformation, demonstrating that GTPase inhibitor activity can be harnessed therapeutically.
Inhibition of Drp1 GTPase in mitochondrial fission
In simple terms: Drp1 is a GTPase that splits mitochondria; inhibiting its GTPase activity reduces excessive mitochondrial fragmentation.
Drpitor1a is a novel Drp1 GTPase inhibitor that reduces pulmonary hypertension by blocking mitochondrial fission. Drp1 GTPase activity is required for its oligomerization and membrane constriction, and its inhibition preserves mitochondrial function in disease models. This illustrates how GTPase inhibitor activity can be targeted to modulate organelle dynamics in cardiovascular disease.
Regulation by metabolic and kinase signaling
In simple terms: Cellular metabolism and kinases can turn GTPase inhibitors on or off, linking energy status to GTPase signaling.
The metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism, effectively reducing GTPase inhibitor activity and promoting cancer. Glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria for T cell memory development, a process that involves GTPase regulation. Casein kinase 1δ targeting suppresses oncogenic NRAS-driven melanoma, indicating that kinase pathways intersect with GTPase inhibitor activity. These examples show that GTPase inhibitor activity is not static but is dynamically regulated by cellular context [2, 3, 5].
Allosteric inhibition of LRRK2
In simple terms: LRRK2 is a kinase and GTPase; allosteric inhibitors can block its GTPase activity without competing with GTP.
Allosteric inhibition of LRRK2 is an active area of drug discovery, with inhibitors binding outside the catalytic site to reduce GTPase activity. LRRK2 hyperactivation is linked to Parkinson's disease, and GTPase inhibitor activity is a promising therapeutic strategy. This subsection highlights the diversity of GTPase inhibitor mechanisms, from small molecules to endogenous proteins.
Key Genes Involved in GO:0005095 GTPase inhibitor activity
The following genes and proteins are central to GTPase inhibitor activity, either as GTPases whose hydrolysis is inhibited or as inhibitors themselves.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KRAS | Small GTPase; inhibited by switch II pocket binders | Oncogenic mutant KRAS(G12D) is a prime target for GTPase inhibitors. |
| Rac1 | Rho-family GTPase; activated by LDHA | Metabolic regulation of Rac1 drives cancer. |
| Drp1 | Dynamin-related GTPase for mitochondrial fission | Drpitor1a inhibits Drp1 GTPase in pulmonary hypertension. |
| LRRK2 | Kinase and GTPase; allosteric inhibition | Therapeutic target for Parkinson's disease. |
| NRAS | Small GTPase; oncogenic in melanoma | CK1δ targeting suppresses NRAS-driven melanoma. |
| LDHA | Metabolic enzyme; activates Rac1 | Links glycolysis to GTPase signaling. |
| AMPK | Energy sensor; coupled to SENP1-Sirt3 | Regulates T cell memory via GTPase-related pathways. |
| SENP1 | DeSUMOylase; mitochondrial signaling | Part of AMPK-SENP1-Sirt3 axis. |
| Sirt3 | Mitochondrial deacetylase | Regulates T cell memory development. |
| CK1δ | Casein kinase 1 delta | Targeting suppresses NRAS-driven melanoma. |
| eEF2 | Elongation factor 2 GTPase | Inhibition affects protein translation in cancer. |
| RAS | Family of small GTPases | Pharmacological restoration of GTP hydrolysis. |
| GAPs | GTPase-activating proteins | Oppose GTPase inhibitor activity. |
| GEFs | Guanine nucleotide exchange factors | Activate GTPases by promoting GTP loading. |
| Drpitor1a | Small molecule Drp1 GTPase inhibitor | Tool compound for pulmonary hypertension. |
| Switch II pocket binders | Allosteric KRAS inhibitors | Freeze KRAS(G12D) in inactive state. |
How Is GTPase inhibitor activity Regulated?
GTPase inhibitor activity is regulated at multiple levels. Metabolic enzymes such as LDHA can activate Rac1 GTPase, effectively reducing GTPase inhibitor activity and promoting cancer. Glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria, which influences T cell memory development through GTPase-related pathways. Kinase signaling, such as casein kinase 1δ, can modulate NRAS-driven melanoma, indicating cross-talk between phosphorylation and GTPase inhibition. Allosteric inhibitors of LRRK2 and KRAS(G12D) demonstrate that pharmacological regulation of GTPase inhibitor activity is achievable [6, 8]. These regulatory layers ensure that GTPase signaling is tuned to cellular energy status and environmental cues [2, 3, 5].
GTPase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer (pancreatic, lung, colorectal) | Point-mutation knock-in of KRAS(G12D) in cell lines |
| Drp1 | Pulmonary hypertension | Overexpression of Drp1 with Drpitor1a treatment |
| LRRK2 | Parkinson's disease | Knock-in of LRRK2(G2019S) in neurons |
| NRAS | Melanoma | CRISPR knockout of CK1δ in NRAS-mutant melanoma cells |
| Rac1 | Cancer metabolism | LDHA knockout or overexpression in cancer cells |
Cancer
Oncogenic mutations in KRAS and NRAS lock GTPases in active states, and GTPase inhibitor activity is a therapeutic strategy to restore hydrolysis [1, 6]. Switch II pocket inhibitors allosterically freeze KRAS(G12D) and arrest the GTPase cycle, suppressing tumor growth. LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer, linking metabolism to GTPase inhibition. Casein kinase 1δ targeting suppresses oncogenic NRAS-driven melanoma, highlighting kinase-GTPase crosstalk. Elongation factor 2 (eEF2) GTPase is a promising therapeutic target in protein translation for cancer.
Pulmonary hypertension
Drp1 GTPase inhibitor Drpitor1a reduces pulmonary hypertension by blocking excessive mitochondrial fission. This demonstrates that GTPase inhibitor activity can be targeted to treat cardiovascular disease.
Neurodegeneration
LRRK2 hyperactivation is linked to Parkinson's disease, and allosteric inhibition of LRRK2 GTPase activity is a therapeutic approach. GTPase inhibitor activity thus plays a protective role in neurodegeneration.
Immunology and T cell memory
Glucose limitation activates AMPK-coupled SENP1-Sirt3 signaling in mitochondria for T cell memory development, a process that involves GTPase regulation. This links GTPase inhibitor activity to immune memory.
From GTPase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a GTPase inhibitor gene activate GTPase signaling? | CRISPR knockout cell line |
| Does a specific point mutation in KRAS alter drug sensitivity? | Point-mutation knock-in |
| Can a GTPase inhibitor be tagged for localization studies? | Tagged knock-in |
| Does overexpression of Drp1 mimic pulmonary hypertension? | Overexpression cell model |
| Which genes modulate NRAS-driven melanoma? | CRISPR library screening |
| How does LDHA regulate Rac1 GTPase? | Knockout and rescue experiments |
How to Study the GTPase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTP hydrolysis assay | Release of orthophosphate from GTP | Quantify GTPase inhibitor potency |
| CRISPR knockout | Loss-of-function of GTPase inhibitor genes | Test causal role in cancer |
| Point-mutation knock-in | Effect of specific mutations on GTPase activity | Model KRAS(G12D) |
| Overexpression | Gain-of-function of GTPases or inhibitors | Study Drp1 in pulmonary hypertension |
| CRISPR library screening | Identify modifiers of GTPase signaling | Discover novel targets |
| Immunoblotting | Protein expression and phosphorylation | Analyze AMPK-SENP1-Sirt3 axis |
| Metabolic assays | LDHA activity and lactate production | Link metabolism to Rac1 activation |
| Allosteric inhibitor profiling | Binding and conformational changes | Develop LRRK2 inhibitors |
CRISPR knockout and point-mutation knock-in
CRISPR knockout of GTPase inhibitor genes or point-mutation knock-in of oncogenic GTPases such as KRAS(G12D) allows causal testing of GTPase inhibitor activity in disease models [1, 6]. These models are essential for validating drug targets and understanding resistance mechanisms.
Pharmacological inhibition and biochemical assays
Small molecule inhibitors like Drpitor1a and switch II pocket binders are used to probe GTPase inhibitor activity in vitro and in vivo [4, 6]. GTP hydrolysis assays measure the release of orthophosphate and can quantify inhibitor potency.
Metabolic and signaling profiling
LDHA-mediated activation of Rac1 GTPase can be studied using metabolic assays and Rac1 activity pull-downs. AMPK-coupled SENP1-Sirt3 signaling is analyzed by immunoblotting and mitochondrial function assays.
Bioinformatics and library screening
CRISPR library screening identifies genes that modulate GTPase inhibitor activity, and bioinformatics pipelines prioritize candidates for follow-up. These approaches accelerate target discovery in cancer and neurodegeneration.
How CRISPR Can Be Used to Study GO:0005095 GTPase inhibitor activity
Knockout
CRISPR knockout of GTPase inhibitor genes or GTPases themselves is used to determine loss-of-function phenotypes in cancer and cardiovascular disease [1, 5]. For example, knocking out CK1δ suppresses NRAS-driven melanoma, validating the pathway.
Point Mutation
Point-mutation knock-in of KRAS(G12D) or LRRK2(G2019S) creates isogenic models to test allele-specific GTPase inhibitor activity and drug sensitivity [6, 8]. These models are critical for precision medicine.
Knock-in
Tagged knock-in of Drp1 or other GTPases allows visualization of localization and dynamics in live cells. Knock-in of reporter genes can monitor GTPase inhibitor activity in real time.
Overexpression
Overexpression of LDHA or Drp1 mimics disease states and tests whether GTPase inhibitor activity can reverse phenotypes [2, 4]. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports GTPase inhibitor activity Research
Researchers studying GTPase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in disease or whether its inhibition can reverse a phenotype. EDITGENE provides validated CRISPR cell models to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for GTPase inhibitor activity research.
Frequently Asked Questions About GTPase inhibitor activity
What is GTPase inhibitor activity?
GTPase inhibitor activity (GO:0005095) is a molecular function that stops, prevents, or reduces the activity of any enzyme that catalyzes the hydrolysis of GTP to GDP and orthophosphate.
What genes are involved in GTPase inhibitor activity?
Key genes include KRAS, Rac1, Drp1, LRRK2, NRAS, LDHA, and CK1δ, among others [1, 2, 4, 5, 6, 8].
How does GTPase inhibitor activity relate to cancer?
Oncogenic mutations in KRAS and NRAS lock GTPases in active states; GTPase inhibitor activity can restore hydrolysis and suppress tumor growth [1, 6].
What diseases are associated with GTPase inhibitor activity?
Cancer, pulmonary hypertension, Parkinson's disease, and immune memory disorders are linked to GTPase inhibitor activity [1, 2, 4, 8].
What is the synonym for GO:0005095?
The synonym is GIP (GTPase inhibitor protein).
How can I study GTPase inhibitor activity in the lab?
Use CRISPR knockout, point-mutation knock-in, overexpression, and pharmacological inhibitors like Drpitor1a [4, 6].
What is the role of Drp1 GTPase inhibitor in pulmonary hypertension?
Drpitor1a inhibits Drp1 GTPase activity, reducing mitochondrial fission and improving pulmonary hypertension.
How does LDHA regulate Rac1 GTPase?
LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer.
What is the mechanism of KRAS(G12D) inhibition?
Switch II pocket inhibitors allosterically freeze the KRAS(G12D) nucleotide-binding site and arrest the GTPase cycle.
What CRISPR models are available for GTPase inhibitor research?
EDITGENE offers knockout, point-mutation knock-in, tagged knock-in, overexpression, and library screening services [1, 4, 5].
Conclusion
GTPase inhibitor activity (GO:0005095) is a fundamental molecular function that controls the duration and intensity of GTPase signaling. Its dysregulation contributes to cancer, pulmonary hypertension, and neurodegeneration, making it a high-value target for therapeutic intervention [1, 4, 8]. CRISPR-based models and pharmacological tools are accelerating our understanding of this activity, and EDITGENE provides the cell models needed to translate these insights into new treatments [1, 5, 6].
References
- 1. Cuevas-Navarro A et al.. 2025. Pharmacological restoration of GTP hydrolysis by mutant RAS.. Nature 637(8044):224-229 PMID: 39476862
- 2. Liu J et al.. 2022. Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer.. Nat Metab 4(12):1830-1846 PMID: 36536137
- 3. He J et al.. 2021. Glucose limitation activates AMPK coupled SENP1-Sirt3 signalling in mitochondria for T cell memory development.. Nat Commun 12(1):4371 PMID: 34272364
- 4. Wu D et al.. 2024. Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension.. Hypertension 81(10):2189-2201 PMID: 39162036
- 5. Wen Y et al.. 2024. Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.. Nat Commun 15(1):10088 PMID: 39572526
- 6. Kim HN et al.. 2025. Switch II Pocket Inhibitor Allosterically Freezes KRAS(G12D) Nucleotide-binding Site and Arrests the GTPase Cycle.. J Mol Biol 437(14):169162 PMID: 40268231
- 7. Jia X et al.. 2024. Elongation factor 2 in cancer: a promising therapeutic target in protein translation.. Cell Mol Biol Lett 29(1):156 PMID: 39707196
- 8. Soliman A et al.. 2020. Allosteric inhibition of LRRK2, where are we now.. Biochem Soc Trans 48(5):2185-2194 PMID: 33079169
